Clinical Trial Update: Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase 1/2 study of pembrolizumab with or without the mesothelin-targeting antibody-drug conjugate anetumab ravtansine in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Anetumab Ravtansine (anetumab ravtansine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pleural Malignant Mesothelioma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-16